Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Pricing ‘Biggest Offenders’ Are Annual Increases On Widely Used Brands

Executive Summary

Express Scripts Chief Medical Officer Steve Miller suggests that caps on annual price increases could significantly ease payer concerns over drug pricing.

Advertisement

Related Content

Why Is Drug Pricing Higher In US? Study Takes Aim At R&D Argument
Why Is Drug Pricing Higher In US? Study Takes Aim At R&D Argument
Drug Pricing ‘Opacity,’ Degrees Of Transparency Debated By National Academies Panel
Senate Committee Closes Books On 2016 Pricing Investigation; PBMs In Hot Seat Next?
Lilly’s Insulin Discounts Target High-Deductible Insurance Gaps
Trump’s Drug Pricing Remarks: A Gambit For Industry Self-Restraint?
Bridging The Drug Price Divide: Ideas And Approaches Debated At PSA
The Super Bowl of Mismanaging Congressional Investigations: Shkreli Vs. Valeant

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119691

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel